SG11201903431SA - Sstr-targeted conjugates and particles and formulations thereof - Google Patents
Sstr-targeted conjugates and particles and formulations thereofInfo
- Publication number
- SG11201903431SA SG11201903431SA SG11201903431SA SG11201903431SA SG11201903431SA SG 11201903431S A SG11201903431S A SG 11201903431SA SG 11201903431S A SG11201903431S A SG 11201903431SA SG 11201903431S A SG11201903431S A SG 11201903431SA SG 11201903431S A SG11201903431S A SG 11201903431SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- conjugates
- conj
- massachusetts
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- General Preparation And Processing Of Foods (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MUNRO III HO I1111 011001 0 01111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2018/081521 Al 03 May 2018 (03.05.2018) WIP0 I PCT (51) International Patent Classification: House Rd, Bernardsville, New Jersey 07924 (US). SEARS, A61K 47/64 (2017.01) C07K 14/72 (2006.01) Chris; 3 Leslie Rd., Belmont, Massachusetts 02478 (US). A61P 35/00 (2006.01) (74) Agent: WARD, Donna T. et al.; DT WARD, PC, 142A (21) International Application Number: Main Street, Groton, Massachusetts 01450 (US). PCT/US2017/058701 (81) Designated States (unless otherwise indicated, for every (22) International Filing Date: kind of national protection available): AE, AG, AL, AM, 27 October 2017 (27.10.2017) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (25) Filing Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (26) Publication Language: English HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (30) Priority Data: KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 62/414,481 28 October 2016 (28.10.2016) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (71) Applicant: TARVEDA THERAPEUTICS, INC. SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, [US/US]; 134 Coolidge Avenue, Watertown, Massachusetts TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 02472 (US). (84) Designated States (unless otherwise indicated, for every (72) Inventors: SHINDE, Rajesh R.; 110 Stearns Hill Rd, kind of regional protection available): ARIPO (BW, GH, Waltham, Massachusetts 02451 (US). ALARGOVA, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, _ Rossitza G.; 148 Newton St., Apt.4, Brighton, Massachu- UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, setts 02135 (US). LIM SOO, Patrick; 64 Garfield Place, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = Unit B, Ridgewood, New Jersey 07450 (US). SWERY- EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, DA-KRAWIEC, Beata; 46 Littlefield Lane, Marlborough, = Massachusetts 01752 (US). ALLAND, Leila; 102 Carriage = (54) Title: SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF Fig. 3 HCC-33 Xenograft efficacy Vehicle 4 wikm. = 2000 *).0.:. Conj. 57 1.0mg/kg = — 1800 .. % 1600 i Conj. 57 0.5mg/kg = — E 1400 . Conj. 57 0.33mg/kg ..,,,.. ' I ' = 1200 i , ...e. , Conj. 57 O.Smg/kg2x's/week = '5 1000 > Conj. 57 0.25mg/kg2x's/week E 800 = 2 - 600 = (i.i °.° 400 • w 200 > .' _ — 0 ,. , 1-1 0 3 6 9 12 15 18 21 24 27 30 Days 1-1 ei kr) 1-1 (57) : Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding C moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved - --- GC temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of , 1 making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject 0 in need thereof are provided, for example, to treat or prevent cancer. ei O [Continued on next page] WO 2018/081521 Al MIDEDIMOM0101011EFIDINIRMEOHOIHOIIIMEMOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662414481P | 2016-10-28 | 2016-10-28 | |
PCT/US2017/058701 WO2018081521A1 (en) | 2016-10-28 | 2017-10-27 | Sstr-targeted conjugates and particles and formulations thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201903431SA true SG11201903431SA (en) | 2019-05-30 |
Family
ID=62024057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201903431SA SG11201903431SA (en) | 2016-10-28 | 2017-10-27 | Sstr-targeted conjugates and particles and formulations thereof |
Country Status (12)
Country | Link |
---|---|
US (2) | US11213590B2 (en) |
EP (1) | EP3532104A4 (en) |
JP (2) | JP2019532091A (en) |
KR (1) | KR20190075938A (en) |
CN (1) | CN109890423A (en) |
AU (1) | AU2017348313B2 (en) |
CA (1) | CA3039065A1 (en) |
IL (2) | IL299532A (en) |
MX (1) | MX2019004963A (en) |
SG (1) | SG11201903431SA (en) |
TW (1) | TW201828992A (en) |
WO (1) | WO2018081521A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112292126A (en) * | 2018-06-01 | 2021-01-29 | 塔弗达治疗有限公司 | Combination therapy |
JP2022525785A (en) * | 2019-03-18 | 2022-05-19 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | Non-hydrolyzable, non-cleavable, stable linker and its uses for precision treatment |
CA3143373A1 (en) * | 2019-06-25 | 2020-12-30 | Tarveda Therapeutics, Inc. | Sstr-targeted conjugates and formulations thereof |
WO2022174171A1 (en) * | 2021-02-15 | 2022-08-18 | Anp Technologies, Inc. | Pharmaceutical composition containing taxane nanoaggregates and use thereof |
WO2022232124A1 (en) * | 2021-04-26 | 2022-11-03 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Targeted alpha particle therapy for somatostatin receptor 2 positive neuroendocrine tumors and metastases |
CN114748481B (en) * | 2022-05-12 | 2023-12-05 | 中国人民解放军海军军医大学 | Application of terluostat hippurate in preparing medicines for resisting tick-borne encephalitis virus, west nile virus, yellow fever virus and chikungunya fever virus infection |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5998154A (en) * | 1995-07-07 | 1999-12-07 | The University Of Texas System | Somatostatin receptor peptide antigens and antibodies |
US7666424B2 (en) * | 2001-10-17 | 2010-02-23 | Sloan-Kettering Institute For Cancer Research | Methods of preparing and using single chain anti-tumor antibodies |
US20070025910A1 (en) * | 2005-07-29 | 2007-02-01 | Norenberg Jeffrey P | Anticancer therapy |
CA2724534A1 (en) * | 2008-05-14 | 2009-11-19 | Ipsen Pharma S.A.S. | Pharmaceutical compositions of somatostatin-dopamine conjugates |
AU2012240448A1 (en) * | 2011-04-01 | 2013-03-28 | Immunogen, Inc. | Compositions and methods for treatment of ovarian, peritoneal, and fallopian tube cancer |
WO2013039916A1 (en) * | 2011-09-12 | 2013-03-21 | The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Compositions for and methods of treatment and enhanced detection of non-pituitary tumors |
CA2936792C (en) | 2014-01-29 | 2022-03-29 | Cosmo Technologies Limited | Liquid composition in the form of emulsion or microemulsion for rectal administration containing at least one dye, and its use in a diagnostic endoscopic procedure of sigmoid colon and/or rectum |
WO2016004043A1 (en) * | 2014-06-30 | 2016-01-07 | Blend Therapeutics, Inc. | Targeted conjugates and particles and formulations thereof |
SG11201610880RA (en) * | 2014-06-30 | 2017-01-27 | Tarveda Therapeutics Inc | Targeted conjugates and particles and formulations thereof |
BR112017028552A2 (en) * | 2015-06-30 | 2018-09-04 | Tarveda Therapeutics Inc | particles and conjugates and formulations thereof |
-
2017
- 2017-10-27 TW TW106137137A patent/TW201828992A/en unknown
- 2017-10-27 MX MX2019004963A patent/MX2019004963A/en unknown
- 2017-10-27 AU AU2017348313A patent/AU2017348313B2/en not_active Ceased
- 2017-10-27 CN CN201780067017.0A patent/CN109890423A/en active Pending
- 2017-10-27 US US16/345,306 patent/US11213590B2/en active Active
- 2017-10-27 EP EP17864950.5A patent/EP3532104A4/en not_active Withdrawn
- 2017-10-27 JP JP2019522709A patent/JP2019532091A/en active Pending
- 2017-10-27 IL IL299532A patent/IL299532A/en unknown
- 2017-10-27 CA CA3039065A patent/CA3039065A1/en not_active Abandoned
- 2017-10-27 WO PCT/US2017/058701 patent/WO2018081521A1/en unknown
- 2017-10-27 KR KR1020197012310A patent/KR20190075938A/en not_active Application Discontinuation
- 2017-10-27 SG SG11201903431SA patent/SG11201903431SA/en unknown
-
2019
- 2019-04-02 IL IL265770A patent/IL265770A/en unknown
-
2021
- 2021-11-04 US US17/518,794 patent/US20220054647A1/en active Pending
-
2022
- 2022-11-25 JP JP2022187945A patent/JP2023010992A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3532104A1 (en) | 2019-09-04 |
TW201828992A (en) | 2018-08-16 |
US20190262460A1 (en) | 2019-08-29 |
US20220054647A1 (en) | 2022-02-24 |
IL299532A (en) | 2023-02-01 |
US11213590B2 (en) | 2022-01-04 |
EP3532104A4 (en) | 2020-06-24 |
CN109890423A (en) | 2019-06-14 |
KR20190075938A (en) | 2019-07-01 |
JP2019532091A (en) | 2019-11-07 |
AU2017348313A1 (en) | 2019-04-18 |
MX2019004963A (en) | 2019-09-26 |
CA3039065A1 (en) | 2018-05-03 |
IL265770A (en) | 2019-06-30 |
WO2018081521A1 (en) | 2018-05-03 |
AU2017348313B2 (en) | 2021-10-21 |
JP2023010992A (en) | 2023-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201903431SA (en) | Sstr-targeted conjugates and particles and formulations thereof | |
SG11201806515RA (en) | Eribulin-based antibody-drug conjugates and methods of use | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201901126UA (en) | Combination therapy for cancer | |
SG11201807472TA (en) | Amanitin conjugates | |
SG11201804934PA (en) | Novel Compounds | |
SG11201811150WA (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
SG11201810034XA (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | |
SG11201804384UA (en) | Geometric configurations for gastric residence systems | |
SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201808676RA (en) | Methods of treating pediatric cancers | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201811209QA (en) | Oral gastroretentive formulations and uses thereof | |
SG11201909837YA (en) | Methods for treating lung disorders | |
SG11201907693VA (en) | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | |
SG11201408240TA (en) | Treatment of motor and movement disorder side effects associated with parkinson's disease treatments | |
SG11201909840TA (en) | Treatment of epithelial cysts by intracystic injection of antineoplastic particles | |
SG11201902988UA (en) | Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof | |
SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
SG11201811482YA (en) | Double targeted constructs to affect tumor kill | |
SG11201809788VA (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer |